Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2015
March 2015, Vol 6, No 2
March 2015, Vol 6, No 2
In the Literature - March 2015
In the Literature
March 2015, Vol 6, No 2
Read Article
AR-V7 Predicts Chemotherapy Sensitivity in Metastatic Prostate Cancer
By
Phoebe Starr
Personalized Medicine
,
Prostate Cancer
,
Solid Tumors
March 2015, Vol 6, No 2
Orlando, FL—Experts are hopeful that the field of prostate cancer will soon be catching up to breast cancer and some other tumor types with regard to genomic markers. A study featured at the 2015 Genitourinary Cancers Symposium suggests that the androgen receptor (AR) abnormality known as “AR-V7” will turn out to be a predictive marker to help in treatment selection for patients with metastatic castration-resistant prostate cancer (CRPC).
Read Article
Value of New Drugs for Hematologic Cancers—Improving Quality, Extending Survival
By
Wayne Kuznar
Economics & Value
,
Economics of Cancer Care
,
Hematologic Cancers
March 2015, Vol 6, No 2
Although often criticized as being overly expensive, innovations in drug development for hematologic malignancies meet standard benchmarks for cost-effectiveness, delivering value for their cost, suggest a team of health economics researchers led by Peter J. Neumann, ScD, Director, the Center for the Evaluation of Value and Risk in Health, Tufts Medical Center, Boston (Saret CJ, et al. Blood. 2015 Feb 5. Epub ahead of print).
Read Article
ASSURE Trial: No Role for Adjuvant Sorafenib or Sunitinib in Locally Advanced Kidney Cancer
By
Phoebe Starr
Genitourinary Cancers Symposium
March 2015, Vol 6, No 2
Orlando, FL—Surprisingly, the use of adjuvant sorafenib (Nexavar) and sunitinib (Sutent) failed to extend disease-free survival (DFS) in patients with locally advanced kidney cancer who are at high risk for recurrence, according to initial results of the ASSURE study. The ASSURE trial is the first and largest study investigating the use of adjuvant tyrosine kinase inhibitors/vascular endothelial growth factor (VEGF) inhibitors in kidney cancer.
Read Article
High-Quality Cancer Care Focus of ASCO’s Medicaid Reform Recommendations
By
Rosemary Frei, MSc
Health Policy
,
Policies & Guidelines
March 2015, Vol 6, No 2
Late last year, the American Society of Clinical Oncology (ASCO) issued a policy statement on Medicaid reform, with recommendations on ensuring quality of care for all patients with cancer, including the underserved population, while also improving provider reimbursement to ensure value-based care. ASCO’s poicy statement advocates for the expansion of Medicaid coverage to all Americans with cancer, an increase in Medicaid payment rates to reach those of Medicare, and a greater emphasis on rewarding providers for the delivery of quality care.
Read Article
Cyramza (Ramucirumab) Approved for the Treatment of Advanced Gastric Cancer and Metastatic Non–Small-Cell Lung Cancer
By
Loretta Fala
Drug Updates
March 2015, Vol 6, No 2
Gastric cancer and lung cancer impose a substantial burden on patients. In light of the high mortality rate and quality-of-life issues associated with these 2 types of cancer, there is a marked need for additional therapeutic options to improve outcomes for patients with gastric or lung cancer.
Read Article
A Conversation with Alberta Hickman, a Lung Cancer Survivor Who Benefited from Cancer Prehabilitation
By
Julie K. Silver, MD
Cancer Rehabilitation
March 2015, Vol 6, No 2
Timothy Sherwood, MD, the thoracic surgeon who was featured in Part 2 of this series, referred Alberta Hickman for prehabilitation before operating on her after she was diagnosed with lung cancer. Alberta received her care at Mary Washington Hospital in Fredericksburg, VA, which recently adopted the STAR Program, a best practices cancer rehabilitation model of care. The medical team published Alberta’s story as a case report, because she did so well and her physical function improved after surgery compared with her baseline status before the operation. Moreover, she had a shorter-than-usual hospital length of stay for this type of surgery. This is Alberta’s perspective about cancer prehabilitation in her own words.
Read Article
More Bad News for Erythropoiesis-Stimulating Agents in Chemotherapy-Induced Anemia
By
Charles Bankhead
Breast Cancer
,
Solid Tumors
March 2015, Vol 6, No 2
San Antonio, TX—Adding an erythropoiesis-stimulating agent (ESA) to best supportive care failed to demonstrate noninferiority for progression-free survival (PFS) compared with best supportive care alone in patients with metastatic breast cancer, in a clinical trial known as EPO-ANE-3010 that was requested by the FDA.
Read Article
Lowering Dietary Fat Increases Long-Term Survival in Women with Hormone-Negative Breast Cancer
By
Alice Goodman
Breast Cancer
,
Solid Tumors
March 2015, Vol 6, No 2
San Antonio, TX—Results of a new nutrition study show that women who reduced their intake of dietary fat for 5 years after being diagnosed with early breast cancer had significantly lower rates of death from all causes compared with controls, at 15 years of follow-up; this reduction was seen specifically in women with hormone receptor (HR)-negative breast cancer. No long-term effect of dietary fat reduction on mortality was observed in women with HR-positive breast cancer. The results of the study, called Women’s Intervention Nutrition Study (WINS), were presented at the 2014 San Antonio Breast Cancer Symposium.
Read Article
Monitoring Response to TKI Therapy by PCR Improves Outcomes in Chronic Myeloid Leukemia
By
Wayne Kuznar
Hematologic Malignancies
,
Leukemia
March 2015, Vol 6, No 2
Disease progression is slower and overall survival (OS) is greater in patients with chronic myeloid leukemia (CML) who are being monitored for their response to tyrosine kinase inhibitor (TKI) therapy and show good adherence. However, few clinicians monitor response and adherence to oral TKI treatment in patients with CML.
Read Article
Page 1 of 3
1
2
3
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma